FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data

Forte Biosciences shares surged after early-stage data showed FB102 significantly improved facial depigmentation in vitiligo, alongside a favorable safety profile. The positive readout is a major catalyst for the company’s pipeline progress, likely driving near-term stock momentum.

Analysis

Forte Biosciences shares surged after early-stage data showed FB102 significantly improved facial depigmentation in vitiligo, alongside a favorable safety profile. The positive readout is a major catalyst for the company’s pipeline progress, likely driving near-term stock momentum.